Inicio
Información del autor
Autor Luis Vicente Syro Moreno
Comentario :
Médico Neurocirujano, Hospital Pablo Tobón Uribe
|
Documentos disponibles escritos por este autor (77)
Refinar búsqueda
Título : Clinical biology of the pituitary adenoma Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2022 Títulos uniformes : Endocrine Reviews Idioma : Inglés (eng) Palabras clave : pituitary adenoma acromegaly prolactinoma Cushing’s disease aggressive pituitary tumor hypothalamus Resumen : All endocrine glands are susceptible to neoplastic growth, yet the health consequences of these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent and overwhelmingly benign, exhibiting a spectrum of diverse behaviors and impact on health. To understand the clinical biology of these common yet often innocuous neoplasms, we review pituitary physiology, and adenoma epidemiology, pathophysiology, behavior, and clinical consequences. The anterior pituitary develops in response to a range of complex brain signals integrating with intrinsic ectodermal cell transcriptional events that together determine gland growth, cell type differentiation, and hormonal production, in turn maintaining optimal endocrine health. Pituitary adenomas occur in ten percent of the population; however, the overwhelming majority remain harmless during life. Triggered by somatic or germline mutations, disease-causing adenomas manifest pathogenic mechanisms that disrupt intra-pituitary signaling to promote benign cell proliferation associated with chromosomal instability. Cellular senescence acts as a mechanistic buffer protecting against malignant transformation, an extremely rare event. It is estimated that fewer than one thousandth of all pituitary adenomas cause clinically significant disease. Adenomas variably and adversely affect morbidity and mortality depending on cell type, hormone secretory activity, and growth behavior. For most clinically apparent adenomas, multimodal therapy controlling hormone secretion and adenoma growth lead to improved quality of life and normalized mortality. The clinical biology of pituitary adenomas and particularly their benign nature stands in marked contrast to other tumors of the endocrine system such as thyroid and neuroendocrine tumors. Mención de responsabilidad : Shlomo Melmed, Ursula B Kaiser, M Beatriz Lopes, Jerome Bertherat, Luis V Syro, Gerald Raverot, Martin Reincke, Gudmundur Johannsson, Albert Beckers, Maria Fleseriu, Andrea Giustina, John A H Wass, Ken K Y Ho Referencia : Endocr Rev. 2022 Apr 8;bnac010. DOI (Digital Object Identifier) : 10.1210/endrev/bnac010 PMID : 35395078 Derechos de uso : CC BY-NC-ND En línea : https://academic.oup.com/edrv/advance-article/doi/10.1210/endrev/bnac010/6565598 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6028 Clinical biology of the pituitary adenoma [documento electrónico] / Luis Vicente Syro Moreno, . - 2022.
Obra : Endocrine Reviews
Idioma : Inglés (eng)
Palabras clave : pituitary adenoma acromegaly prolactinoma Cushing’s disease aggressive pituitary tumor hypothalamus Resumen : All endocrine glands are susceptible to neoplastic growth, yet the health consequences of these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent and overwhelmingly benign, exhibiting a spectrum of diverse behaviors and impact on health. To understand the clinical biology of these common yet often innocuous neoplasms, we review pituitary physiology, and adenoma epidemiology, pathophysiology, behavior, and clinical consequences. The anterior pituitary develops in response to a range of complex brain signals integrating with intrinsic ectodermal cell transcriptional events that together determine gland growth, cell type differentiation, and hormonal production, in turn maintaining optimal endocrine health. Pituitary adenomas occur in ten percent of the population; however, the overwhelming majority remain harmless during life. Triggered by somatic or germline mutations, disease-causing adenomas manifest pathogenic mechanisms that disrupt intra-pituitary signaling to promote benign cell proliferation associated with chromosomal instability. Cellular senescence acts as a mechanistic buffer protecting against malignant transformation, an extremely rare event. It is estimated that fewer than one thousandth of all pituitary adenomas cause clinically significant disease. Adenomas variably and adversely affect morbidity and mortality depending on cell type, hormone secretory activity, and growth behavior. For most clinically apparent adenomas, multimodal therapy controlling hormone secretion and adenoma growth lead to improved quality of life and normalized mortality. The clinical biology of pituitary adenomas and particularly their benign nature stands in marked contrast to other tumors of the endocrine system such as thyroid and neuroendocrine tumors. Mención de responsabilidad : Shlomo Melmed, Ursula B Kaiser, M Beatriz Lopes, Jerome Bertherat, Luis V Syro, Gerald Raverot, Martin Reincke, Gudmundur Johannsson, Albert Beckers, Maria Fleseriu, Andrea Giustina, John A H Wass, Ken K Y Ho Referencia : Endocr Rev. 2022 Apr 8;bnac010. DOI (Digital Object Identifier) : 10.1210/endrev/bnac010 PMID : 35395078 Derechos de uso : CC BY-NC-ND En línea : https://academic.oup.com/edrv/advance-article/doi/10.1210/endrev/bnac010/6565598 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6028 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001869 AC-2022-034 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-034Adobe Acrobat PDFPituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? / Luis Vicente Syro Moreno
Título : Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2021 Títulos uniformes : Journal of the Endocrine Society Idioma : Inglés (eng) Palabras clave : Pituitary neoplasm neuroendocrine pituitary adenoma tumor Resumen : The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with concern by some stakeholder groups. The Pituitary Society coordinated the Pituitary Neoplasm Nomenclature (PANOMEN) workshop to address the topic. Experts in pituitary developmental biology, pathology, neurosurgery, endocrinology, and oncology, including representatives nominated by the Endocrine Society, European Society of Endocrinology, European Neuroendocrine Association, Growth Hormone Research Society, and International Society of Pituitary Surgeons. Clinical epidemiology, disease phenotype, management, and prognosis of pituitary adenomas differ from that of most NETs. The vast majority of pituitary adenomas are benign and do not adversely impact life expectancy. A nomenclature change to PitNET does not address the main challenge of prognostic prediction, assigns an uncertain malignancy designation to benign pituitary adenomas, and may adversely affect patients. Due to pandemic restrictions, the workshop was conducted virtually, with audiovisual lectures and written précis on each topic provided to all participants. Feedback was collated and summarized by Content Chairs and discussed during a virtual writing meeting moderated by Session Chairs, which yielded an evidence-based draft document sent to all participants for review and approval. There is not yet a case for adopting the PitNET nomenclature. The PANOMEN Workshop recommends that the term adenoma be retained and that the topic be revisited as new evidence on pituitary neoplasm biology emerges. Mención de responsabilidad : Ken Ho, Maria Fleseriu, Ursula Kaiser, Roberto Salvatori, Thierry Brue, M Beatriz Lopes, Pamela Kunz, Mark Molitch, Sally A Camper, Mônica Gadelha, Luis V Syro, Edward Laws, Martin Reincke, Hiroshi Nishioka, Ashley Grossman, Ariel Barkan, Felipe Casanueva, John Wass, Adam Mamelak, Laurence Katznelson, Aart J van der Lely, Sally Radovick, Martin Bidlingmaier, Margaret Boguszewski, Jens Bollerslev, Andrew R Hoffman, Nelson Oyesiku, Gerald Raverot, Anat Ben-Shlomo, Rob Fowkes, Ilan Shimon, Hidenori Fukuoka, Alberto M Pereira, Yona Greenman, Anthony P Heaney, Mark Gurnell, Gudmundur Johannsson, Robert Y Osamura, Michael Buchfelder, Maria Chiara Zatelli, Marta Korbonits, Philippe Chanson, Nienke Biermasz, David R Clemmons, Niki Karavitaki, Marcello D Bronstein, Peter Trainer, Shlomo Melmed Referencia : J Endocr Soc. 2021 Feb 9;5(3):bvaa205. DOI (Digital Object Identifier) : 10.1210/jendso/bvaa205 PMID : 33604494 Derechos de uso : CC BY-NC-ND En línea : https://academic.oup.com/jes/article/5/3/bvaa205/6131724 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5765 Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? [documento electrónico] / Luis Vicente Syro Moreno, . - 2021.
Obra : Journal of the Endocrine Society
Idioma : Inglés (eng)
Palabras clave : Pituitary neoplasm neuroendocrine pituitary adenoma tumor Resumen : The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with concern by some stakeholder groups. The Pituitary Society coordinated the Pituitary Neoplasm Nomenclature (PANOMEN) workshop to address the topic. Experts in pituitary developmental biology, pathology, neurosurgery, endocrinology, and oncology, including representatives nominated by the Endocrine Society, European Society of Endocrinology, European Neuroendocrine Association, Growth Hormone Research Society, and International Society of Pituitary Surgeons. Clinical epidemiology, disease phenotype, management, and prognosis of pituitary adenomas differ from that of most NETs. The vast majority of pituitary adenomas are benign and do not adversely impact life expectancy. A nomenclature change to PitNET does not address the main challenge of prognostic prediction, assigns an uncertain malignancy designation to benign pituitary adenomas, and may adversely affect patients. Due to pandemic restrictions, the workshop was conducted virtually, with audiovisual lectures and written précis on each topic provided to all participants. Feedback was collated and summarized by Content Chairs and discussed during a virtual writing meeting moderated by Session Chairs, which yielded an evidence-based draft document sent to all participants for review and approval. There is not yet a case for adopting the PitNET nomenclature. The PANOMEN Workshop recommends that the term adenoma be retained and that the topic be revisited as new evidence on pituitary neoplasm biology emerges. Mención de responsabilidad : Ken Ho, Maria Fleseriu, Ursula Kaiser, Roberto Salvatori, Thierry Brue, M Beatriz Lopes, Pamela Kunz, Mark Molitch, Sally A Camper, Mônica Gadelha, Luis V Syro, Edward Laws, Martin Reincke, Hiroshi Nishioka, Ashley Grossman, Ariel Barkan, Felipe Casanueva, John Wass, Adam Mamelak, Laurence Katznelson, Aart J van der Lely, Sally Radovick, Martin Bidlingmaier, Margaret Boguszewski, Jens Bollerslev, Andrew R Hoffman, Nelson Oyesiku, Gerald Raverot, Anat Ben-Shlomo, Rob Fowkes, Ilan Shimon, Hidenori Fukuoka, Alberto M Pereira, Yona Greenman, Anthony P Heaney, Mark Gurnell, Gudmundur Johannsson, Robert Y Osamura, Michael Buchfelder, Maria Chiara Zatelli, Marta Korbonits, Philippe Chanson, Nienke Biermasz, David R Clemmons, Niki Karavitaki, Marcello D Bronstein, Peter Trainer, Shlomo Melmed Referencia : J Endocr Soc. 2021 Feb 9;5(3):bvaa205. DOI (Digital Object Identifier) : 10.1210/jendso/bvaa205 PMID : 33604494 Derechos de uso : CC BY-NC-ND En línea : https://academic.oup.com/jes/article/5/3/bvaa205/6131724 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5765 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001690 AC-2021-016 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2021-016Adobe Acrobat PDF
Título : Pituitary society expert Delphi consensus: operative workflow in endoscopic transsphenoidal pituitary adenoma resection Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2021 Títulos uniformes : Pituitary Idioma : Inglés (eng) Palabras clave : Consensus Delphi Endoscopic endonasal Endoscopic transsphenoidal surgery Pituitary Pituitary adenoma Skull base surgery Resumen : Purpose: Surgical workflow analysis seeks to systematically break down operations into hierarchal components. It facilitates education, training, and understanding of surgical variations. There are known educational demands and variations in surgical practice in endoscopic transsphenoidal approaches to pituitary adenomas. Through an iterative consensus process, we generated a surgical workflow reflective of contemporary surgical practice. Methods: A mixed-methods consensus process composed of a literature review and iterative Delphi surveys was carried out within the Pituitary Society. Each round of the survey was repeated until data saturation and > 90% consensus was reached. Results: There was a 100% response rate and no attrition across both Delphi rounds. Eighteen international expert panel members participated. An extensive workflow of 4 phases (nasal, sphenoid, sellar and closure) and 40 steps, with associated technical errors and adverse events, were agreed upon by 100% of panel members across rounds. Both core and case-specific or surgeon-specific variations in operative steps were captured. Conclusions: Through an international expert panel consensus, a workflow for the performance of endoscopic transsphenoidal pituitary adenoma resection has been generated. This workflow captures a wide range of contemporary operative practice. The agreed "core" steps will serve as a foundation for education, training, assessment and technological development (e.g. models and simulators). The "optional" steps highlight areas of heterogeneity of practice that will benefit from further research (e.g. methods of skull base repair). Further adjustments could be made to increase applicability around the world. Mención de responsabilidad : Hani J. Marcus, Danyal Z. Khan, Anouk Borg, Michael Buchfelder, Justin S. Cetas, Justin W. Collins, Neil L. Dorward, Maria Fleseriu, Mark Gurnell, Mohsen Javadpour, Pamela S. Jones, Chan Hee Koh, Hugo Layard Horsfall, Adam N. Mamelak, Pietro Mortini, William Muirhead, Nelson M. Oyesiku, Theodore H. Schwartz, Saurabh Sinha, Danail Stoyanov, Luis V. Syro, Georgios Tsermoulas, Adam Williams, Mark J. Winder, Gabriel Zada & Edward R. Laws Referencia : Pituitary. 2021 Dec;24(6):839-853. DOI (Digital Object Identifier) : 10.1007/s11102-021-01162-3 PMID : 34231079 Derechos de uso : CC BY En línea : https://link.springer.com/article/10.1007%2Fs11102-021-01162-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5816 Pituitary society expert Delphi consensus: operative workflow in endoscopic transsphenoidal pituitary adenoma resection [documento electrónico] / Luis Vicente Syro Moreno, . - 2021.
Obra : Pituitary
Idioma : Inglés (eng)
Palabras clave : Consensus Delphi Endoscopic endonasal Endoscopic transsphenoidal surgery Pituitary Pituitary adenoma Skull base surgery Resumen : Purpose: Surgical workflow analysis seeks to systematically break down operations into hierarchal components. It facilitates education, training, and understanding of surgical variations. There are known educational demands and variations in surgical practice in endoscopic transsphenoidal approaches to pituitary adenomas. Through an iterative consensus process, we generated a surgical workflow reflective of contemporary surgical practice. Methods: A mixed-methods consensus process composed of a literature review and iterative Delphi surveys was carried out within the Pituitary Society. Each round of the survey was repeated until data saturation and > 90% consensus was reached. Results: There was a 100% response rate and no attrition across both Delphi rounds. Eighteen international expert panel members participated. An extensive workflow of 4 phases (nasal, sphenoid, sellar and closure) and 40 steps, with associated technical errors and adverse events, were agreed upon by 100% of panel members across rounds. Both core and case-specific or surgeon-specific variations in operative steps were captured. Conclusions: Through an international expert panel consensus, a workflow for the performance of endoscopic transsphenoidal pituitary adenoma resection has been generated. This workflow captures a wide range of contemporary operative practice. The agreed "core" steps will serve as a foundation for education, training, assessment and technological development (e.g. models and simulators). The "optional" steps highlight areas of heterogeneity of practice that will benefit from further research (e.g. methods of skull base repair). Further adjustments could be made to increase applicability around the world. Mención de responsabilidad : Hani J. Marcus, Danyal Z. Khan, Anouk Borg, Michael Buchfelder, Justin S. Cetas, Justin W. Collins, Neil L. Dorward, Maria Fleseriu, Mark Gurnell, Mohsen Javadpour, Pamela S. Jones, Chan Hee Koh, Hugo Layard Horsfall, Adam N. Mamelak, Pietro Mortini, William Muirhead, Nelson M. Oyesiku, Theodore H. Schwartz, Saurabh Sinha, Danail Stoyanov, Luis V. Syro, Georgios Tsermoulas, Adam Williams, Mark J. Winder, Gabriel Zada & Edward R. Laws Referencia : Pituitary. 2021 Dec;24(6):839-853. DOI (Digital Object Identifier) : 10.1007/s11102-021-01162-3 PMID : 34231079 Derechos de uso : CC BY En línea : https://link.springer.com/article/10.1007%2Fs11102-021-01162-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5816 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001750 AC-2021-066 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2021-066Adobe Acrobat PDF
Título : Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID‐19 pandemic—an international perspective Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2020 Títulos uniformes : Pituitary Idioma : Inglés (eng) Palabras clave : Acromegaly COVID-19 Cushing’s disease Pituitary disease and surgery Prolactinomas SARS-CoV-2 Resumen : Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral strain that has caused the coronavirus disease 2019 (COVID-19) pandemic, has presented healthcare systems around the world with an unprecedented challenge. In locations with significant rates of viral transmission, social distancing measures and enforced 'lockdowns' are the new 'norm' as governments try to prevent healthcare services from being overwhelmed. However, with these measures have come important challenges for the delivery of existing services for other diseases and conditions. The clinical care of patients with pituitary disorders typically involves a multidisciplinary team, working in concert to deliver timely, often complex, disease investigation and management, including pituitary surgery. COVID-19 has brought about major disruption to such services, limiting access to care and opportunities for testing (both laboratory and radiological), and dramatically reducing the ability to safely undertake transsphenoidal surgery. In the absence of clinical trials to guide management of patients with pituitary disease during the COVID-19 pandemic, herein the Professional Education Committee of the Pituitary Society proposes guidance for continued safe management and care of this population. Mención de responsabilidad : Maria Fleseriu, Michael Buchfelder, Justin S. Cetas, Pouneh K. Fazeli, Susana M. Mallea-Gil, Mark Gurnell, Ann McCormack, Maria M. Pineyro, Luis V. Syro, Nicholas A. Tritos & Hani J. Marcus Referencia : Pituitary. 2020 Aug;23(4):327-337. DOI (Digital Object Identifier) : 10.1007/s11102-020-01059-7 PMID : 32556793 Derechos de uso : CC BY En línea : https://link.springer.com/article/10.1007/s11102-020-01059-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5121 Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID‐19 pandemic—an international perspective [documento electrónico] / Luis Vicente Syro Moreno, . - 2020.
Obra : Pituitary
Idioma : Inglés (eng)
Palabras clave : Acromegaly COVID-19 Cushing’s disease Pituitary disease and surgery Prolactinomas SARS-CoV-2 Resumen : Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral strain that has caused the coronavirus disease 2019 (COVID-19) pandemic, has presented healthcare systems around the world with an unprecedented challenge. In locations with significant rates of viral transmission, social distancing measures and enforced 'lockdowns' are the new 'norm' as governments try to prevent healthcare services from being overwhelmed. However, with these measures have come important challenges for the delivery of existing services for other diseases and conditions. The clinical care of patients with pituitary disorders typically involves a multidisciplinary team, working in concert to deliver timely, often complex, disease investigation and management, including pituitary surgery. COVID-19 has brought about major disruption to such services, limiting access to care and opportunities for testing (both laboratory and radiological), and dramatically reducing the ability to safely undertake transsphenoidal surgery. In the absence of clinical trials to guide management of patients with pituitary disease during the COVID-19 pandemic, herein the Professional Education Committee of the Pituitary Society proposes guidance for continued safe management and care of this population. Mención de responsabilidad : Maria Fleseriu, Michael Buchfelder, Justin S. Cetas, Pouneh K. Fazeli, Susana M. Mallea-Gil, Mark Gurnell, Ann McCormack, Maria M. Pineyro, Luis V. Syro, Nicholas A. Tritos & Hani J. Marcus Referencia : Pituitary. 2020 Aug;23(4):327-337. DOI (Digital Object Identifier) : 10.1007/s11102-020-01059-7 PMID : 32556793 Derechos de uso : CC BY En línea : https://link.springer.com/article/10.1007/s11102-020-01059-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5121 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001380 AC-2020-057 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2020-057.pdfAdobe Acrobat PDF
Título : Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2019 Títulos uniformes : Pituitary Idioma : Inglés (eng) Palabras clave : Adenoma Contrast Gadolinium Imaging Neuroendocrinologists Neurosurgeons Pituitar Safety Survey Tumor Resumen : Purpose: In view of mounting attention related to possible brain retention of gadolinium-based contrast agents (GBCAs) in patients with normal renal function, our purpose was to detail results from a survey of pituitary experts to assess: 1) the timing interval and frequency of pituitary magnetic resonance imaging (MRI) following surgical and/or medical and/or radiation therapy of pituitary tumors, 2) awareness of the types of GBCAs used and their possible safety issues. Methods: The Pituitary Society Education Committee composed a survey with 12 multiple choice questions, 8 of which specifically addressed the time interval and frequency of MRI in the longitudinal management of pituitary tumors. The survey was distributed at two meetings; the International Pituitary Neurosurgeons Society conference in San Diego, CA, on February 18th, 2018, and the Pituitary Society Membership and Career Development Forum, Chicago, IL on March 18th, 2018. Results: There is consensus among pituitary endocrinologists and neurosurgeons that long-term repeated imaging is recommended in most pituitary tumors, although the precise strategy of timing varied depending on the specialist group and the specific clinical context of the adenoma. The data also suggest that International Pituitary Neurosurgeons Society neurosurgeons, as well as Pituitary Society neuroendocrinologists, are sometimes unaware of which contrast agents are used by their institution, and many are also unaware that evidence of long-term brain retention has been reported with the use of GBCAsin patients with normal function. Conclusions: International pituitary endocrinologists and pituitary neurosurgeons experts suggest ongoing MRIs for the management of pituitary tumors; strategies vary based on clinical context, but also on individual experience and practice. Mención de responsabilidad : Lisa B Nachtigall, Niki Karavitaki, Katja Kiseljak-Vassiliades, Luma Ghalib, Hidenori Fukuoka, Luis V Syro, Daniel Kelly, Maria Fleseriu Referencia : Pituitary. 2019 Feb;22(1):37-45. DOI (Digital Object Identifier) : 10.1007/s11102-018-0924-0 PMID : 30456434 En línea : https://link.springer.com/article/10.1007%2Fs11102-018-0924-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4128 Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey [documento electrónico] / Luis Vicente Syro Moreno, . - 2019.
Obra : Pituitary
Idioma : Inglés (eng)
Palabras clave : Adenoma Contrast Gadolinium Imaging Neuroendocrinologists Neurosurgeons Pituitar Safety Survey Tumor Resumen : Purpose: In view of mounting attention related to possible brain retention of gadolinium-based contrast agents (GBCAs) in patients with normal renal function, our purpose was to detail results from a survey of pituitary experts to assess: 1) the timing interval and frequency of pituitary magnetic resonance imaging (MRI) following surgical and/or medical and/or radiation therapy of pituitary tumors, 2) awareness of the types of GBCAs used and their possible safety issues. Methods: The Pituitary Society Education Committee composed a survey with 12 multiple choice questions, 8 of which specifically addressed the time interval and frequency of MRI in the longitudinal management of pituitary tumors. The survey was distributed at two meetings; the International Pituitary Neurosurgeons Society conference in San Diego, CA, on February 18th, 2018, and the Pituitary Society Membership and Career Development Forum, Chicago, IL on March 18th, 2018. Results: There is consensus among pituitary endocrinologists and neurosurgeons that long-term repeated imaging is recommended in most pituitary tumors, although the precise strategy of timing varied depending on the specialist group and the specific clinical context of the adenoma. The data also suggest that International Pituitary Neurosurgeons Society neurosurgeons, as well as Pituitary Society neuroendocrinologists, are sometimes unaware of which contrast agents are used by their institution, and many are also unaware that evidence of long-term brain retention has been reported with the use of GBCAsin patients with normal function. Conclusions: International pituitary endocrinologists and pituitary neurosurgeons experts suggest ongoing MRIs for the management of pituitary tumors; strategies vary based on clinical context, but also on individual experience and practice. Mención de responsabilidad : Lisa B Nachtigall, Niki Karavitaki, Katja Kiseljak-Vassiliades, Luma Ghalib, Hidenori Fukuoka, Luis V Syro, Daniel Kelly, Maria Fleseriu Referencia : Pituitary. 2019 Feb;22(1):37-45. DOI (Digital Object Identifier) : 10.1007/s11102-018-0924-0 PMID : 30456434 En línea : https://link.springer.com/article/10.1007%2Fs11102-018-0924-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4128 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000739 AC-2018-026 Archivo digital Producción Científica Artículos científicos Disponible PermalinkPermalinkPermalinkPermalinkPermalinkPermalinkPermalinkPermalinkPermalinkPermalink
